Cedilla Therapeutics Appoints Delphine Collin, Ph.D., as Vice President, Biomolecular Sciences

Cedilla Therapeutics Appoints Delphine Collin, Ph.D., as Vice President, Biomolecular Sciences

CAMBRIDGE, Mass. May 14, 2019Cedilla Therapeutics today announced the appointment of Delphine Collin, Ph.D., as vice president, biomolecular sciences. In this role, she will advance Cedilla’s work to develop and leverage the biophysical and biochemical understanding of ligand-induced stabilization and degradation of therapeutically relevant protein targets.

“Delphine is an accomplished leader with a proven track record of developing successful discovery strategies and advancing preclinical projects,” said Brian Jones, Ph.D., Cedilla’s chief scientific officer. “Her deep expertise in protein characterization and protein-small molecule interactions will be invaluable as we explore promising new tools to modulate protein stability.”

Collin most recently served as chief innovation officer of HarkerBIO, a contract research organization focused on the structural enablement of early discovery research. Previously, she served as senior principal scientist at Boehringer Ingelheim (BI) and led a biophysics group focused on lead identification and optimization in the small molecule drug discovery group. While at BI, Collin also started her own consulting firm, Delphine Collin Consulting, LLC., where she supported companies with specialized biophysical approaches to drug discovery. Prior to BI, Collin was a research fellow at Merck & Co. Collin holds a Ph.D. in biophysical chemistry and doctorate in pharmaceutical sciences from the University of Paris XI, France.

“Cedilla is pursuing several exciting new avenues for protein degradation, and I’m delighted to join the team,” Collin said. “We’re committed to broadening the reach of small molecule therapeutics to address cancer and other diseases caused by protein dysregulation.”

About Cedilla Therapeutics

Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action. The approach harnesses intrinsic degradation pathways that are upstream of ubiquitination. Cedilla is focused on destabilizing oncoprotein targets using a product engine that is also applicable to targets outside of oncology. Cedilla was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass.

For more information, please visit www.cedillatx.com or follow us on LinkedIn.

Media Contact:

Stephanie Simon
Ten Bridge Communications